Preview

Журнал микробиологии, эпидемиологии и иммунобиологии

Расширенный поиск

АНТИГЕНЫ ПОВЕРХНОСТНЫХ СТРУКТУР HAEMOPHILUS INFLUENZAE КАК ПЕРСПЕКТИВНЫЕ КАНДИДАТ-ВАКЦИНЫ

https://doi.org/10.36233/0372-9311-2017-4-82-90

Полный текст:

Аннотация

Несмотря на то, что вакцина против Haemophilus influenzae b (Hib) давно и успешно применяется, получение вакцины против нетипируемых штаммов Haemophilus influenzae (NTHi) находится только в стадии разработки. Сложности этой работы обусловлены отличительными чертами NTHi по сравнению с Hib: отсутствие полисахаридной капсулы, высокий уровень антигенной гетерогенности и особенности развития патогенеза, который включает распространение по организму со слизистых оболочек дыхательных путей. В настоящее время с целью создания вакцины активно проводятся исследования 15 поверхностных структур NTHi, Среди них белки РЕ, Р2, Р6, PD, пузырьки поверхности мембраны (OMVs) и другие. Практическое применение в настоящее время получил лишь белок PD, который был использован в качестве носителя с антигенной функцией в конъюгированных полисахаридных вакцинах против пневмонии (Prevenar; PHiD-CV). Вакцинация этими препаратами позволила снизить общую заболеваемость острым отитом у детей на 33 - 52%. Однако этот результат не может рассматриваться как окончательный, поэтому исследования и апробирование кандидат-вакцин продолжаются.

Об авторах

Н. Н. Овенко
НИИ вакцин и сывороток им. И.И.Мечникова
Россия


Н. Е. Ястребова
НИИ вакцин и сывороток им. И.И.Мечникова
Россия


Список литературы

1. Akkoyunlu М., Ruan М., Forsgren A. Distribution of protein D, an immunoglobulin D-binding protein, in Haemophilus strains. Infect. Immun. 1991,59: 1231-1238.

2. Arbing M. A., Hanrahan J. W., Coulton J. W. Mutagenesis identifies amino acid residues in extracellular loops and within the barrel lumen that determine voltage gating of porin from Haemophilus influenzae type b. Biochemistry. 2001, 40: 14621-14628.

3. Barenkamp S.J., Jr., Munson R.S., Granoff D.M. Outer membrane protein and biotype analysis of pathogenic nontypabie Haemophilus influenzae. Infect. Immun. 1982, 36: 535-540.

4. Bell J., Grass S., Jeanteur D. Diversity of the P2 protein among nontypeable Haemophilus influenzae isolates. Infect. Immun. 1994, 62: 2639-2643.

5. Black S., Shinefield H., Fireman B. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 2000, 19: 187.

6. Burrage M., Robinson A., Borrow R. et al. Effect ofvaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect. Immun. 2002, 70: 4946-4954.

7. Cantisani M., Vitiello M., Falanga A. et al. Peptides complementary to the active loop of porin P2 from Haemophilus influenzae modulate its activity. Int. J. Nanomedicine. 2012, 7: 2361-2371.

8. Concino M. F., Goodgal S. H. DNA-binding vesicles released from the surface of a competence-deficient mutant of Haemophilus influenzae. J. Bacteriol. 1982, 152: 441-450.

9. Coulton J.W., Chin A.C., Vachon V. Recombinant porin of Haemophilus influenzae tvpe b. J. Infect. Dis. 1992, 165 (Suppl.): 188-191.

10. Croxtall J.D., Keating G.M. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr. Drugs. 2009, 11 (5): 349-357.

11. Druim B., Dankert J., Jansen H.M. et al. Genetic analysis of the diversity in outer membrane protein P2 of non-encapsulated Haemophilus influenzae. Microb. Pathos. 1993, 14: 451 -462.

12. Duim B., Ruiter P, Bowler L.D. et al. Sequence variation in the hpd gene of nonencapsulated Haemophilus influenzae isolated from patients with chronic bronchitis. Gene. 1997, 191: 57-60.

13. Erwin A.L., Smith A.L. Nontypeable Haemophilus influenzae: understanding virulence and commensal behavior. Trends Microbiol. 2007, 15: 355-362.

14. Fleischmann R.D., Adams M.D., White O. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995, 269: 496-512.

15. Forsgren A., Riesbeck K., Janson H. Protein D of Haemophilus influenzae: a protective non-tvpeable H. influenzae antigen and a earner for pneumococcal conjugate vaccines. Clin. Infect. Dis. 2008,46 (5): 726-731.

16. GuX.X., Rudy S.F., Chu C. et al. Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine. 2003, 21(Issues 17-18): 2107-2114.

17. Hallstrom X, Blom A.M., Zipfel P.F. et al. Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance. J. Immunol. 2009, 183 (4): 2593-2601.

18. Hallstrom X, Singh B., Resman F. et al. Haemophilus influenzae protein E binds to the extracellular matrix by concurrently interacting with laminin and vitronectin. J. Infect. Dis. 2011, 204(7): 1065-1074.

19. Harrison A., Dyer D.W., Gillaspy A. et al. Genomic sequence of an otitis media isolate of nontypeable Haemophilus influenzae: comparative study with H. influenzae serotvpe d, strain KW20. J. Bacteriol. 2005, 187: 4627-4636.

20. Janson H., Heden L.O., Grubb A. et al. Protein D, an immunoglobulin D-binding protein of Haemophilus influenzae: cloning, nucleotide sequence, and expression in Escherichia coli. Infect. Immun. 1991, 59: 119-125.

21. Kim S.H., Kim K.S., Lee S.R. et al. Stmctural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim. Biophys. Acta. 2009, 1788: 2150-2159.

22. KulpA., KuehnM.J. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu. Rev. Microbiol. 2010, 64: 163-184.

23. Lysenko E.S., Ratner A.J., Nelson A.L. et al. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog. 2005. 1(1): el.

24. Morris S.K., Moss W.J., Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet. Infect. Dis. 2008, 8: 435-443.

25. Murphy T. F., Dudas К. C, Mylotte J. M. etal. A subtyping system for nontypable Haemophilus influenzae based on outer-membrane proteins. J. Infect. Dis. 1983, 147: 838-846.

26. Murphy T.F. Vaccines for nontypeable Haemophilus influenzae: the Future is now. Clin. Vaccine Immunol. 2015, 22 (5): 459-466.

27. Nurkka A., Joensuu J., Henckaerts I. et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr. Infect. Dis. J. 2004, 23: 1008-1014.

28. Pichichero M.E., Kaur R., Casey J.R. et al. Antibody response to Haemophilus influenzae outer membrane protein D, P6, and OMP26 after nasopharyngeal colonization and acute otitis media in children. Vaccine. 2010, 28 (44): 7184-7192.

29. Poolman J.T., Bakaletz L., Cripps A. et al. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine. 2000, 19 (Suppl 1): 108-115.

30. Post D.M., Zhang D., Eastvold J.S. et al. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J Biol. Chem. 2005, 280: 38383-38394.

31. Prymula R., Peeters R, Chrobok V. et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study Lancet. 2006, 367: 740-748.

32. Ronander E., Brant M., Eriksson E. et al. Nontypeable Haemophilus influenzae adhesin protein E: characterization and biological activity. J. Infect. Dis. 2009, 199: 522-531.

33. Saint N., Lou K. L., Widmer C. et al. Structural and functional characterization of OmpF porin mutants selected for larger pore size. II. Functional characterization. J. Biol. Chem. 1996,271:20676-20680.

34. Sexton K., Lennon D., Oster P. et al. The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic. N. Z, Med. J. 2004, 117: 1015.

35. Singh B., Jalalvand F, Morgelin M. et al. Haemophilus influenzae protein E recognizes the C-terminal domain ofvitronectinand modulates the membrane attack complex. Mol. Microbiol. 2011,81 (1): 80-98.

36. Singhl B., Brantl M. et al. Protein E of Haemophilus influenzae is a ubiquitous highly conserved adhesin. J. Infect. Dis. 2010, 201 (3): 414-419.

37. Sharpe S.W., Kuehn M.J., Mason K.M. Elicitation of epithelial cell-derived immune effectors by outer membrane vesicles of nontypeable Haemophilus influenzae. Infect. Immun. 2011, 79:4361-4369.

38. Sun J., Chen J., Cheng Z. et al. Biological activities of antibodies elicited by lipooligosaccha-ride based-conjugate vaccines of nontypeable Haemophilus influenzae in an otitis media model. Vaccine. 2000, 18 (Issue 13): 1264-1272.

39. Wu T, Chen J., Murphy T.F. et al. Investigation of nontypeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines. Vaccine. 2005,23 (Issue 44): 5177-5185.

40. Yi K., Murphy T. F. Importance of an immunodominant surface-exposed loop on outer membrane protein P2 of nontypeable Haemophilus influenzae. Infect. Immun. 1997, 65: ISO-155.


Рецензия

Просмотров: 163


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0372-9311 (Print)
ISSN 2686-7613 (Online)